* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download grand-round-ik-141016-v1 - Continuous Learning, Education
Survey
Document related concepts
Neuropharmacology wikipedia , lookup
Environmental impact of pharmaceuticals and personal care products wikipedia , lookup
Adherence (medicine) wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Environmental persistent pharmaceutical pollutant wikipedia , lookup
Prescription costs wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Electronic prescribing wikipedia , lookup
Discovery and development of cephalosporins wikipedia , lookup
Transcript
Ildiko Kustos Medical Microbiology Consultant COCH 14 Oct 2016 Modern medical practice relies on the widespread availability of effective antimicrobials to prevent and treat infections in humans Penicillin 1928 Sir Alexander Fleming Antibiotics were first prescribed in 1940s 1970s: the battle of the bugs versus the drugs was over. 1967 William H Stewart US Surgeon General “it is time to close the book on infectious diseases” The Government de-emphasized bacterial research and the drug industry, sensing a saturated market, shifted resources elsewhere. Resistance has eventually been seen to all abx that have been developed Diverse mechanisms have been demonstrated UK Prime Minister commissioned a review on antimicrobial resistance to address the growing global problem of drugresistant infections. Report from 2014 Rapid emergence of resistant bacteria is occurring worldwide Bacterial infections are getting a threat again ‘Antibiotic crisis’ has been attributed to: ◦ Overuse and misuse of antimicrobials ◦ Lack of new drug development by the pharmaceutical industry CDC declared in 2013 that the human race is now in the ‘post-antibiotic era’ that could have ‘catastrophic consequences’ C. Lee Ventola MS: The Antibiotic Resistance Crisis P&T 2015; 40(4): 277-283 Significant threat to patient safety ◦ ◦ ◦ ◦ worse outcomes longer hospitalizations Significantly higher mortality rates greater healthcare expenditures Poor outcomes are multifactorial ◦ ?greater severity of underlying illness ◦ delays in initiation of effective therapy ◦ lack of effective antimicrobial therapy new infectious diseases have been discovered nearly every year over the past 30 years there have been very few new antibiotics developed encourage development of new drugs looking after the current supply of antibiotics is equally important. ◦ better hygiene measures to prevent infections ◦ prescribing fewer antibiotics ◦ making sure they are only prescribed when needed Threat Report 2013 CDC Each year in the US at least 2 million people become infected with multi-resistant bacteria at least 23,000 people die each year as a direct result of these infections. Many more people die from other conditions that were complicated by an antibioticresistant infection The threats are ranked in categories: urgent, serious, and concerning assessed the threats according to seven factors (associated with resistant infections): health impact economic impact how common the infection is a 10-year projection of how common it could become ◦ how easily it spreads ◦ availability of effective antibiotics ◦ and barriers to prevention ◦ ◦ ◦ ◦ Infections classified as urgent threats include: ◦ carbapenem-resistant Enterobacteriaceae (CRE) 9,000 infections/year in US, 600 deaths ◦ drug-resistant gonorrhea 820,000 gonococcal infection / year 246,000 drug resistant gonorrhoea infection 188,600 resistance to tetracycline 11,480 reduced susceptibility to cefixime 3,280 reduced susceptibility to ceftriaxone 2,460 redcued susceptibility to azithromycin ◦ Clostridium difficile 250,000 C. difficile infections/ year 14,000 deaths 2002 2012 700 600 655 500 574 400 419 300 200 311 310 2008 2009 100 0 2010 2011 2012 90 80 78 70 70 60 47 50 37 40 32 30 20 7 10 0 TMP NIT CIP GEN TAZ MER Multidrug-resistant Acinetobacter Drug-resistant Campylobacter Fluconazole-resistant Candida Extended spectrum β-lactamase producing Enterobacteriaceae (ESBLs) Vancomycin-resistant Enterococcus (VRE) Multidrug-resistant Pseudomonas aeruginosa Drug-resistant non-typhoidal Salmonella Drug-resistant Salmonella Typhi Drug-resistant Shigella Methicillin-resistant Staphylococcus aureus (MRSA) Drug-resistant Streptococcus pneumoniae Drug-resistant tuberculosis Vancomycin-resistant Staphylococcus aureus (VRSA) Erythromycin-resistant Group A Clindamycin-resistant Group B Streptococcus Streptococcus Chief Medical Officer has warned that antibiotic resistance could bring a return to the hospital conditions of the 19th century It was said that the problem was a "ticking time-bomb" It should be added to the government's National Risk Register, alongside terrorist threats There are no new classes of antibiotics in the pipelines across the world (and there are very few in development) Drug resistance is growing in part because doctors are prescribing antibiotics in cases where they are not necessary 1. Overuse As early as 1945 Sir A Fleming raised alarm regarding antibiotic overuse (New York Times 6/26/45) Misuse of penicillin could lead to propagation of mutant forms of bacteria that would resist the new miracle drug. Ca.14 % of Staph strains isolated in a London hospital had developed resistance to penicillin by 1946 Epidemiological studies: direct relationship between antibiotic consumption and emergence of resistant strains (Nature, 2013; 495(7440): 141 Selective pressure Over the counter antibiotic prescriptions Patient demands Not completing prescribed courses 2. Inappropriate prescribing Studies have shown that indication, choice or duration of antibiotic treatment is incorrect in 30-50% of cases (Luyt et al, Crit Care 2014, 14(8): 480 Subinhibitory and subtherapeutic antibiotic concentrations can promote the development of antibiotic resistance 3. Extensive agricultural usage Antibiotics used as growth supplements in livestock Estimated 80% of antibiotics used in animals in the US Improve animal health, produce larger yields, and higher quality products Abx used in livestock ingested by humans when consuming food 4. environmental usage Agricultural use affect the environment as antibiotics are excreted in urine and stool by animals Tetracyclines and streptomycin used for spraying fruit trees Number of new antibiotics has declined since 1980s Most of these drugs are in two classes (beta-lactams and quinolones) Technical difficulties – bacterial evolution is uncertain – development of resistance is unpredictable Antibiotics are used for short term treatment – ecomonically not good investment Withhold of new antibiotics in reserve for only the worst cases Complex regulatory procedures, changes in rules, absence of clarity, differences in clinical trial requirements among countries The importance of AMR has been recognised globally for many years. ◦ The first ‘World Health Assembly (WHA) AMR resolution’ was agreed in 1998 and urged Member States to take action to address AMR. ◦ The need to accelerate progress has been acknowledged by both the WHO and European Commission. ◦ The ‘2001 WHO Global Strategy for Containment of AMR’, the ‘2011 EU AMR Strategic Action Plan’ and the ‘2012 EU Council Conclusions’ have all helped to provide a renewed focus on the area WHO Antimicrobial resistance fact sheet 2016 ◦ ◦ ◦ ◦ ◦ ◦ ◦ Antimicrobial resistance is a complex problem Affects all of the society Driven by many interconnected factors Single, isolated interventions have limited impact Coordinated action is required All countries need national action plans on AMR Greater innovation and investment are required in research and development of new antimicrobial medicines, vaccines and diagnostic tools. Published 2016 Includes 28 recommendations regarding implementation of AMS Program ◦ ◦ ◦ ◦ ◦ ◦ ◦ ◦ ◦ ◦ ◦ ◦ Preauthorisation of abx prescription Prospective audit and feedback Facility specific clinical practice guidelines Antibiotic stop orders on prescriptions Computerized clinical decision support Suggest against antibiotic cycling Monitoring and adjustment programs for aminoglycosides Implement programs to increase appropriate use of oral abx and timely transition from IV to oral abx Selective reporting of abx Development of anti biograms Rapid viral testing for respiratory pathogens PCT measurements on ICUs sets out UK actions to address the key challenges to AMR The overarching goal of the Strategy is to slow the development and spread of AMR. It focusses activities around 3 strategic aims: ◦ improve the knowledge and understanding of AMR, ◦ conserve and steward the effectiveness of existing treatments, ◦ stimulate the development of new antibiotics, diagnostics and novel therapies 1. improving infection prevention and control practices 2. optimising prescribing practice 3 improving professional education, training and public engagement 4 developing new drugs, treatments and diagnostics 5 better access to and use of surveillance data 6 better identification and prioritisation of AMR research needs 7 strengthened international collaboration ‘European Antibiotic Awareness Day’ (since 2008) to raise awareness among health professionals and the public GP toolkit – ‘Treat Antibiotics Responsibly, Guidance and Education Tool’ (TARGET) (developed by HPA) ‘Start Smart then Focus’ launched in 2011to provide guidance on antibiotic stewardship in hospitals To improve prescribing, a number of measures relating to usage and choice of antibiotics were developed as part of the ‘Quality, Innovation, Productivity and Prevention’ (QIPP) programme in the NHS. Number of initiatives to promote the responsible use of antibiotics in the veterinary sector AMS Committee had been set up in 2011 AMS Program had been initiated 2011 Antimicrobial Stewardship: Definition “optimal selection, dosage, and duration of antimicrobial treatment that results in the best clinical outcome for the treatment or prevention of infection with minimal toxicity to the patient and minimal impact on subsequent resistance” A multi-faceted approach to influence antimicrobial prescribing, institution-wide to improve outcomes, prevent resistance and minimize excessive cost IDSA Guidelines. Clin Infect Dis 2007;44:159 Antibiotic guidelines ◦ Narrow-spectrum agents for empirical treatment (where appropriate) ◦ Minimize the use of 3rd gen cephalosporins, clindamycin, carbapenems, fluoroquinolones ◦ Give guidance on dosage, duration, for iv to oral switch. Daily review of drug prescriptions by ward Pharmacists Microbiology ward rounds / MDT ◦ ◦ ◦ ◦ ◦ Daily Critical care rounds Daily follow up of patients with positive blood cultures Weekly Haematology MDT Weekly CDT Ward Round Weekly Orthopaedic ward round Trust wide point prevalence antibiotic audits Percentage of patients on antibiotics: Comparison of North West Hospitals: Point prevalence audit Spring 2010 45 39 40 37 35 35 30 30 30 32 31 30 32 30 26 25 % 22 23 22 23 26 23 20 15 10 5 ey er rh Al de C he st ie ld of C ou nt es s M ac cl es f te r ol ch es an M th N or nd kp o st ch e sh rt a H ea ol rp o Li ve e id g % patients receiveing antibiotic therapy te rb r Bl ac ire M nc a M id La C he s ol og nc ro ce nt re fo U H S hi re y al W irr on ri n gt hi re W ar an ca s d an n W ig a on Ea st L Le ig h us t Tr N H S ht W rig C la t So u th po r ta nd in gt O rm sk irk St o Tr af fo ck po rd rt 0 Percentage of Patients on Antibiotic Therapy at different Trusts 45.0% 40.0% 35.0% 30.0% 25.0% 20.0% 15.0% 10.0% 5.0% 0.0% Trust 50 antibiotics per month Data collected by antibiotic Pharmacists Data obtained from Medical notes and MediTech As specified by PHE the review include documented evidence of: ◦ ◦ ◦ ◦ ◦ Stop IV to oral switch Change antibiotic Continue antibiotic OPAT This information can either be documented in the medical notes or electronically on EP system incl: ◦ Antibiotic stopped / changed / restarted / dose adjustment etc on EP ◦ Change in Stop / review date ◦ Change in plan for therapeutic drug monitoring plan e.g. change vancomycin level Month 2016 Documented review of antibiotic prescription (Medical notes OR EP) April 82% May 86% June 88% Reduction in antibiotic consumption per 1,000 admissions There are three parts to this indicator: ◦ Total antibiotic consumption per 1,000 admissions - as measured by Defined Daily Dose (DDD) ◦ Total consumption of carbapenem per 1,000 admissions - as measured by Defined Daily Dose (DDD) ◦ Total consumption of piperacillin-tazobactam per 1,000 admissions - as measured by Defined Daily Dose (DDD) Baseline period/date 2013/14 ◦ (discussions regarding 2015/16 baseline figures) Reduction of 1% or more in total antibiotic consumption against the baseline Reduction of 1% or more in carbapenem usage against the baseline Reduction of 1% or more in piperacillin-tazobactam usage against the baseline Each of the indicators is worth 25% of part 4a with an additional 25% to be paid for submission of consumption data to PHE for years: 2014/15 to 2016/17. Data will be collected quarterly Data will be reported to the commissioner annually 900,000 838639 800,000 700,000 760601 674615 600,000 500,000 400,000 300,000 200,000 100,000 0 2013/14 2014/15 13% increase in 2014/15 10% increase in 2015/16 2015/16 80000 70000 60000 50000 40000 30000 20000 63719 67704 2014/15 2015/16 49412 10000 0 2013/14 29% increase in 2014/15 7% increase in 2015/16 meropenem ertapenem 1200 20000 18000 1000 16000 14000 800 12000 10000 17787 8000 6000 4000 10383 600 400 12186 1109 640 672 2013/14 2014/15 200 2000 0 0 2013/14 2014/15 2015/16 15% increase in 2014/15 46% increase in 2015/16 2015/16 5% increase in 2014/15 65% increase in 2015/16 450000 400000 411167 419789 2015/16 2016/17 350000 300000 250000 200000 150000 100000 50000 0 2% increase compared to 2015/16 (Q1+Q2) 700 9000 8000 600 500 611 512 7000 8310 6925 6000 400 5000 300 4000 3000 200 2000 100 1000 0 0 2015/16 ERTAPENEM 2016/17 19% increase compared to 2015/16 2015/16 MEROPENEM 2016/17 16.6% decrease compared to 2015/16 35000 30000 31574 29946 25000 20000 15000 10000 5000 0 2015/16 2016/17 5% decrease compared to 2015/16 (Q1+Q2) Microbiology input in patients positive blood cultures and other significant results Daily review of patients on Critical Care ?microbiology review of patients on meropenem ?microbiology review of patients on Tazocin >7 days Antibiotic reports Written consultation system for all doctors on Meditech Review antibiotics on ward rounds Review antibiotics (and document) within 72 hrs Stop unnecessary antibiotics Review culture results Narrow the spectrum if possible Switch to oral antibiotics if clinically appropriate Contact microbiology if any concerns